Tumor-targeted apoptosis by a novel spermine analogue, 1,12- diaziridinyl-4,9-diazadodecane, results in therapeutic efficacy and enhanced radiosensitivity of human prostate cancer

Cancer Research

Volumn 58, Issue 21, 1998, Pages 4864-4870

  Eiseman, Julie L ^a   Rogers, Faye A ^b   Guo, Yanping ^c   Kauffman, Jaqueline ^a   Sentz, Dorothy L ^a   Klinger, Matthew F ^a   Callery, Patrick S ^b   Kyprianou, Natasha ^a,c  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,12 DIAZIRIDINYL 4,9 DIAZADODECANE; CISPLATIN; POLYAMINE DERIVATIVE; SPERMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG UPTAKE; GAMMA IRRADIATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RADIOSENSITIVITY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AZIRIDINES; HUMANS; MALE; MICE; MICE, SCID; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; SPERMINE; TUMOR CELLS, CULTURED;

EID: 0032211359     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Wingo, P. A., Tong, T-N., Bolden, S., and Wingo, P. A. Cancer statistics. CA Cancer J. Clin., 47: 5-27, 1997.
2. Raghavan, D. Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin. Oncol., 15: 371-389, 1988.
3. Crawford, E. D., Eisenberger, M. A. McLeod, D. C., Spaulding, J., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., and Goodman, P. J. A control randomized trial of leuprolide with and without flutamide in prostatic cancer. N. Engl. J. Med., 321: 419-424, 1989.
4. Schellhammer, P. F. Radiation therapy for localized prostate cancer: what has been and still remains to he learned, In: T. Stamey (ed.), Monographs in Urology, Vol. 15(5). Stanford, CA: Medical Directions Publishing Co., Inc., 1994.
5. Lelefsky, M. J., Leibel, S. A., Bruman, C. M., Kutchener, G. J., Harrison, A., Happerset, L., and Fuks, Z. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic disease treated with three dimensional conformal radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 29: 755-761, 1994.
6. Stephens, L. C., Hunter, N. R., Ang, K. K., Milas, L., and Meyn, R. E. Development of apoptosis in irradiated murine tumors as a function of time and dose. Radiat. Res., 135: 75-80, 1993.
7. Sklar, N. G., Eddy, H. A., Jacobs, S. C., and Kyprianou, N. Combined antitumor effect of suramin plus irradiation in prostate cancer cells: the role of apoptosis. J. Urol., 150: 1526-1532, 1993.
8. Kyprianou, N. Apoptosis: therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer. World J. Urol., 13: 299-303, 1994.
9. Pegg, A. E. Polyamine metabolism and its importance in neoplastic growth and as target for chemotherapy. Cancer Res., 48: 759-764, 1988.
10. Marton, L. J., and Pegg, A. E. Polyamines as targets for therapeutic intervention. Annu. Rev. Pharmacol. Toxicol., 35: 55-91, 1995.
11. Li, Y., Eiseman, J. L., Sentz, D. L., Rogers, F. A., Pan, S., Hu, L-T., Egorin, M. J., and Callery, P. S. Synthesis and antitumor evaluation of a highly potent cytotoxic DNA cross-linking polyamine analogue, 1,12-diaziridinyl-4, 9-diazadodecane. J. Med. Chem., 39: 339-341, 1996.
12. Heston, W. D. W. Prostatic polyamines and polyamine targeting as a new approach to therapy of prostatic cancer. Cancer Surv., 11: 217-238, 1991.
13. Quemener, V., Blanchard, Y., Chamailllard, L., Havouis, R., Cipolla, B., and Moulinoux, J-Ph. Polyamine deprivation: a new tool in cancer treatment. Anticancer Res., 14: 443-448, 1994.
14. Jain, R. K. Delivery of molecules, particles and cells to solid tumors: A Review. Ann. Biomed. Eng., 24: 457-473, 1996.
15. Seiler, N., and Dezeuere, F. Polyamine transport in mammalian cells. Int. J. Biochem., 22: 211-218, 1990.
16. Seppanen, P. Some properties of the polyamine deprivation-inducible uptake system for methylglyoxal bis(guanylhydrazone) in tumor cells. Acta Chem. Scand., 35: 731-736, 1981.
17. 8-aziridinyl analogues of spermidine. Cancer Res., 54: 742-748, 1994.
18. Li, Y., MacKerell, A. D., Jr., Egorin, M. J., Ballesteros, M. F., Rosen, D. M., Wu, Y-Y., Blamble, D. A., and Callery, P. S. Comparative molecular field analysis-based predictive model of structure-function relationships of polyamine transport inhibitors in L1210 cells. Cancer Res., 57: 234-239, 1997.
19. 1 mice. Cancer Chemother. Pharmacol., 38: 13-20, 1996.
20. Callery, P. S., Egorin, M. J., Li, Y., and Yuan, Z-M. Diaziridinyl polyamine anticancer agents, U. S. patent, 5,612,239, Issued March 17, 1997.
21. Kyprianou, N., King, E., Bradbury, D., and Rhee, J. Bcl-2 overexpression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int. J. Cancer, 70: 341-348, 1997.
22. Tu, H., Borkowski, A., Jacobs, S. C., and Kyprianou, N. Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-β and bcl-2 expression. Int. J. Cancer, 69: 357-363, 1996.
23. Palayoor, S. T., Bump, E. A., Teicher, B. A., and Coleman, C. N. Apoptosis and clonogenic cell death in PC-3 human prostate cancer cells after treatment with γ irradiation and suramin. Radiat. Res., 148: 105-114, 1997.
24. Soler, A. P., Gilliard, G., Megosh, L., George, K., and O'Brien, T. G. Polyamines regulate expression of the neoplastic phenotype in mouse skin. Cancer Res., 58: 1654-1659, 1998.
25. 11-diethylnospermine on a human bladder xenograft in nude athymic mice. Clin. Cancer Res., 3: 1239-1244, 1997.
26. Basu, H. S,. Marton, L. J., Pellarin, M., Deen, D. F., McManis, J. S., Liu, C. Z., Bergeron, R. J., and Feuerstein, B. G. Design and testing of novel cytotoxic polyamine analogues. Cancer Res., 54: 6210-6214, 1994.
27. Igarashi, K., Koga, K., Shiogoiri, T., Ekimoto, H., Kashiwagi, K., and Shirahata, A. Inhibition of the growth of various human and mouse tumor cells by 1,15-bis(ethyl-amino)-4,8,12-triazapentadecane. Cancer Res., 55: 2615-2619, 1995.
28. McCloskey, D. E., Casero, R. A., Woster, P. M., and Davidson, N. E. Induction of programmed cell death in human breast cancer cells by an asymmetrically alkylated polyamine analog. Cancer Res., 55: 3233-3236, 1995.
29. McCloskey, D. E., Yang, J., Woster, P. M., Davidson, N. E., and Casero, R., Jr. Polyamine analogue induction of programmed cell death in human lung tumor cells. Clin. Cancer Res., 2: 441-446, 1996.
30. Kramer, D. L., Fogel-Petrovic M., Diegelman, P., Cooley, J. M., Bernacki, R. J., McCanis, J. S., Bergeron, R. J., and Porter, C. W. Effects of novel spermine analogues on cell cycle progression and apoptosis in MALME-3M human melanoma cells. Cancer Res., 57: 5521-5527, 1997.
31. 14-Bis(ethyl)homospermine. Int. J. Radiat. Oncol. Biol. Phys., 29: 1041-1047, 1994.
32. Jeffers, L., Church, D., Basu, H., Marton, L., and Wilding, G. Effects of the polyamine analogues BE-4-4-4-4, BE-3-7-3 and BE-3-3-3 on the proliferation of three prostate cancer cell lines. Cancer Chemother. Pharmacol. 40: 171-179, 1997.
33. Mi, Z., Kramer, D. L., Miller, J. T., Bergeron, R. J., Bernacki, R., and Porter, C. W. Human prostatic carcinoma cell lines display altered regulation of polyamine transport in response to polyamine analogs and inhibitors. Prostate, 34: 51-60, 1998.
34. Chmura, S. J., Mauceri, H. J., Advani, S., Heiman, R., Beckett, M. A., Nodzenki, E., Quintans, J., Kufe, D. W., and Weichselbaum, R. R. Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing irradiation. Cancer Res., 57: 4340-4347, 1997.
35. Petereit, D. G., Harari, P. M., Contreas, L., Pickart, M. A. Verma, A. K., Gerner, E., W., and Kinsela, T. J. Combining polyamine depletion with radiation therapy for rapidly dividing head and neck tumors: strategies for improved locoregional control. Int. J. Rad. Oncol. Biol. Phys., 28: 891-898, 1994.
36. Fike, J. R., Gobbel, G. T., Marton, L. J., and Sheilham, T. M. Radiation brain injury is reduced by the polyamine inhibitor difluoromethylornithine. Radiat. Res., 138: 99-106, 1994.
37. Kyprianou, N., Mackey, T., Borkowski, A., Amin, P., Jacobs, S. C. Bcl-2/Bax ratio as a marker of therapeutic response to radiation treatment for prostate cancer. Urology, in press, 1998.
38. McDonell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C., Chung, L. W. K., Hsieh, J-T., Tu, S-M., and Campbell, M. L. Expression of the protoncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940-6944, 1992.
39. Rupnow, B. A., Murtha, A. D., Alarcon, R. D., Giaccia, A. J., and Knox, S. J. Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy. Cancer Res., 58: 1779-1784, 1998.